Acorda Therapeutics Inc (ACORQ)

[surf1944]

6:03AM Acorda Therapeutics announces data on AMPYRA presented at 5th joint triennial congress of ECTRIMS and ACTRIMS (ACOR) 21.42 : The poster also presented safety findings from all 483 participants who enrolled in extension studies after participating in either MS-F203 or MS-F204. The tolerability profile reported in the extension studies was similar to that seen in Phase 3 placebo-controlled trials of AMPYRA, with the most common adverse events being urinary tract infection, falls, MS relapse, arthralgia, and peripheral edema. In a sub-analysis of the 348 extension study participants treated with AMPYRA in the Phase 3 trials, four seizure-related events were reported. The second poster, entitled "Dalfampridine Extended Release Tablets: One Year of Post-Marketing Safety Experience in the United States" analyzed all spontaneously reported adverse events in the United States from March 1, 2010 through March 31, 2011. There is a known risk of seizure with dalfampridine. The seizure rate of ~ 5.7/1000 patient-years observed in the post-marketing population, reflecting seizures that have been either reported or confirmed by a healthcare practitioner, was not substantially different from the rate observed in AMPYRA clinical trials.